Anna-Lena Spetz

Company: TIRmed Pharma

Job title: Chief Scientific Officer & Founder

Seminars:

TIRmed’s TIR‑C: Advancing Topical Oligonucleotide Therapy for Atopic Dermatitis into the Clinic 11:00 am

TIR‑C aims to relieve itch and regenerate tissue without systemic side effects, thereby directly modulating skin immune cells (e.g., dendritic, mast cells, IL‑10 induction) Outlining nonclinical toxicology and regulatory approaches for CTA approval ahead of planned Phase I trial in 2026 After Phase I safety and tolerability results TIRmed will prepare for Phase Ib targeting…Read more

day: Day Two AM